Financial Performance - The company's operating revenue for 2025 was CNY 2,716,343.32 million, a decrease of 9.32% compared to 2024[22] - The total profit for 2025 was CNY 252,617.93 million, down by 5.66% from the previous year[22] - The net profit attributable to shareholders for 2025 was CNY 208,443.61 million, reflecting a decline of 3.56% year-over-year[22] - The net cash flow from operating activities for 2025 was CNY 359,373.11 million, a decrease of 6.66% compared to 2024[22] - The basic earnings per share for 2025 were CNY 0.47, a decrease of 4.08% compared to 2024[23] - The weighted average return on net assets for 2025 was 7.78%, down by 0.69 percentage points from the previous year[23] Dividend Distribution - The company plans to distribute a cash dividend of CNY 1.96 per 10 shares, totaling CNY 867 million, which is 41.57% of the net profit attributable to shareholders for 2025[6] - The company does not have any unremedied losses affecting dividend distribution[7] - The company distributed a cash dividend of ¥866,585,540.80, which represents 41.57% of the net profit attributable to ordinary shareholders in the consolidated financial statements of ¥2,084,436,058.90[146] - Over the last three accounting years, the total cash dividend amount (including tax) was ¥2,405,217,009.38, with an average annual net profit of ¥1,976,076,119.09, resulting in a cash dividend ratio of 121.72%[148] Revenue Breakdown - In Q1 2025, the company's operating revenue was CNY 509,612.27 million, with a net profit attributable to shareholders of CNY 54,081.59 million[27] - The total operating revenue for Q2 2025 increased to CNY 622,154.48 million, while the net profit attributable to shareholders was CNY 55,748.06 million[27] - For Q3 2025, the operating revenue reached CNY 634,346.85 million, with a net profit attributable to shareholders of CNY 50,660.87 million[27] - In Q4 2025, the operating revenue surged to CNY 950,229.72 million, but the net profit attributable to shareholders decreased to CNY 47,953.09 million[27] Assets and Liabilities - The total assets at the end of 2025 amounted to CNY 4,919,213.95 million, an increase of 1.99% from the end of 2024[22] - The net assets attributable to shareholders at the end of 2025 were CNY 2,657,784.09 million, up by 1.19% year-over-year[22] - The total assets as of December 31, 2025, were 49.192 billion yuan, with a net asset value of 26.578 billion yuan and a debt-to-asset ratio of 41.83%[37] - Total liabilities increased by CNY 623 million, a growth of 3.12%, mainly due to the recognition of liabilities related to the acquisition of equity in CNOOC[87] Operational Highlights - The company completed 74 large-scale projects during the reporting period, with 31 completed within the year[37] - The overseas market contract value reached 30.843 billion yuan, setting a historical high[41] - The company successfully completed the first deep-water total package project in overseas markets, marking a significant breakthrough[40] - The company has made significant advancements in new energy projects, including the largest deep-sea floating wind power platform and various LNG projects[40] Research and Development - R&D expenses totaled 119.07 million RMB, accounting for 4.38% of total revenue, with no capitalized R&D expenditures[78] - The company employed 2,313 R&D personnel, representing 23.14% of the total workforce[79] - The company successfully applied for 29 major national scientific research projects, enhancing its core competitiveness in strategic emerging industries[80] Corporate Governance - The company has established a robust corporate governance structure, ensuring compliance with relevant laws and regulations, and has revised 27 governance documents during the reporting period[112] - The board of directors focuses on long-term strategic issues and has implemented a closed-loop management system for planning and execution feedback[114] - The company has established a three-tier ESG governance structure centered around the board of directors, enhancing its sustainable development management system and risk response capabilities, receiving 20 ESG-related awards in the past three years[115] Environmental and Social Responsibility - The company planted 10,000 trees in collaboration with Saudi Aramco, covering 5.832 hectares of desert land, expected to absorb 2,400 tons of CO2 over the next decade[153] - In 2025, the company conducted 275 inspections and removed approximately 8 tons of floating plastic waste, contributing to marine ecological protection[153] - The company invested a total of RMB 2.5 billion in bank wealth management products, with no overdue amounts reported[179] Future Outlook and Strategy - The company aims to enhance its core competitiveness and focus on modern industrial chain construction as part of its "14th Five-Year" strategy[100] - The company plans to implement a "1235" development strategy focusing on design leadership, operational management, and internationalization[101] - The company is committed to advancing digital transformation and enhancing its technological capabilities to maintain competitiveness in the energy sector[102] Related Party Transactions - The company committed to conducting related transactions with CNOOC at fair market prices to protect the interests of the listed company and its shareholders[161] - The maximum limit for daily related transactions for 2025 is set at 43.573 billion RMB[167] - The company expects a total of approximately 242 billion RMB in related party transactions by the end of 2025, which accounts for 56% of the estimated amount for that year[168]

Financial Performance - The company's operating revenue for 2025 reached ¥2,319,754,086.04, representing a year-on-year increase of 28.62% compared to ¥1,803,569,661.85 in 2024[26]. - The total profit for 2025 was ¥210,836,301.54, a decrease of 30.88% from ¥305,029,452.61 in 2024[26]. - The net profit attributable to shareholders for 2025 was ¥207,520,637.42, down 29.03% from ¥292,416,562.47 in 2024[26]. - The company achieved a gross profit margin decrease of 5.19 percentage points due to intensified market competition and price pressures[30]. - The company's revenue from storage series chips reached 1.787 billion yuan, a year-on-year increase of 26.10%, with a gross margin of 29.54%, down 5.07 percentage points[50]. - The company achieved a total revenue of 2.32 billion yuan in the reporting period, an increase of 28.62% compared to the same period last year[111]. - The net profit attributable to the parent company was 208 million yuan, a decrease of 29.03% year-on-year, while the net profit excluding non-recurring gains and losses was 165 million yuan, down 38.67% year-on-year[111]. Research and Development - Research and development expenses increased by ¥55,317,800, a rise of 22.86% compared to the previous year, reflecting the company's commitment to product development[31]. - The total R&D expenditure for the current year is approximately ¥297.29 million, an increase of 22.86% compared to the previous year[154]. - R&D expenses amounted to 297 million yuan, accounting for 12.82% of total revenue, reflecting a strong commitment to innovation and product development[112]. - The company has seen a 25.69% increase in R&D and technical personnel compared to the previous year, indicating a focus on strengthening its innovation capabilities[112]. - The company has filed 27 new invention patents and submitted 1 PCT patent during the reporting period, reflecting its commitment to innovation[151]. Acquisitions and Partnerships - The company acquired a 51% stake in Zhuhai Noah Changtian Storage Technology Co., contributing approximately ¥210 million to the consolidated revenue for the reporting period[29]. - The acquisition of 51% of Zhuhai Noah Changtian Storage Technology Co., Ltd. contributed approximately CNY 210 million to the consolidated revenue, with a net profit attributable to the parent company of about CNY 14 million[190]. - The company successfully integrated SkyHigh Memory through a 51% stake acquisition, enhancing its technological strength and market competitiveness in the storage sector[110]. - The company has made strategic acquisitions to enhance its product line and global strategic layout in the memory chip sector[49]. Market and Competitive Landscape - The semiconductor industry is experiencing rapid growth driven by technological advancements and increasing market demand, particularly in AI and storage solutions[83]. - The current storage supercycle is primarily driven by AI, leading to increased demand for high-performance memory products amid supply constraints[84]. - The company faces significant competition in the NOR Flash and EEPROM markets, with established players like Winbond and Macronix holding advantages in revenue scale and R&D investment[168]. - The company is exposed to risks from high supplier concentration, which could affect wafer manufacturing and testing capacity if suppliers face disruptions[173]. Product Development and Innovation - Atmel Corporation reported a series of ARM Cortex-M processors designed for high efficiency and ease of use, aimed at future embedded applications[15]. - The company is focused on enhancing its power management solutions, integrating multiple power management devices into single-chip designs for compact applications[15]. - The company has launched multiple VCM Driver chips for camera modules, achieving mass production and focusing on low power consumption and compact design to meet the demands of lightweight smart devices[75]. - The company has developed a complete engineering capability for NAND Flash products through the acquisition of SHM, enhancing its competitive edge in customized storage solutions[125]. - The company is focusing on upgrading its NOR Flash and EEPROM technologies to maintain competitive advantages in the market[163]. Operational Efficiency and Challenges - The company is currently benefiting from a reduced corporate income tax rate of 15% as a high-tech enterprise, valid for three years, but future changes in tax policy could affect earnings[179]. - The company anticipates a significant increase in depreciation and amortization expenses following the implementation of fundraising projects, which could impact profitability if market conditions worsen[178]. - The company is at risk of product quality issues due to the complexity of the chip industry, which could negatively impact financial performance and brand reputation[170]. - The company faces intensified market competition in the semiconductor industry, which may impact its market position and performance[181]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Lixin Accounting Firm[6]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[4]. - The company has not reported any unremedied losses in the parent company[8]. - The company has not experienced any non-operating fund occupation by controlling shareholders or related parties[10]. - There are no violations of decision-making procedures regarding external guarantees[10].

Financial Performance - The company achieved a consolidated net profit attributable to shareholders of RMB 2,983,113,594.80 for the fiscal year ending December 31, 2025, with a base net profit of RMB 1,155,028,771.93[5]. - A cash dividend of RMB 0.45 per share (before tax) is proposed, amounting to a total distribution of RMB 731,605,927.05 based on a total share capital of 1,625,790,949 shares[6]. - The company retained undistributed profits of RMB 7,263,234,411.77 after accounting for the proposed dividends and legal surplus reserves[5]. - The company plans to allocate 10% of the net profit for the year as statutory surplus reserves, totaling RMB 115,502,877.19[5]. - The company's operating revenue for 2025 reached RMB 77.66 billion, a 3.55% increase from RMB 74.99 billion in 2024[17]. - Net profit attributable to shareholders for 2025 was RMB 2.98 billion, reflecting a 5.21% increase compared to RMB 2.84 billion in 2024[17]. - The total profit amounted to RMB 3,689,925,942.42, reflecting a year-on-year increase of 2.28%[59]. - The net profit attributable to shareholders reached RMB 2,983,113,594.80, with a year-on-year growth of 5.21%[59]. Revenue Growth and Market Expansion - Guangzhou Baiyunshan Pharmaceutical Group reported a significant increase in revenue, achieving a total of CNY 10.5 billion in the last quarter, representing a year-over-year growth of 15%[15]. - The company’s net profit for the same period reached CNY 1.2 billion, reflecting a 20% increase compared to the previous year[15]. - User data indicates that the customer base expanded by 25%, with over 5 million new users acquired in the last quarter[15]. - Future outlook suggests a projected revenue growth of 12% for the upcoming fiscal year, driven by increased demand in both domestic and international markets[15]. - Market expansion efforts include entering two new provinces in China, targeting a 10% increase in market penetration by the end of the year[15]. - The company aims to enhance its brand presence through digital marketing initiatives, expecting a 30% increase in online sales channels[15]. Research and Development - The company is investing CNY 500 million in R&D for new technologies aimed at improving production efficiency and product quality[15]. - The company is focusing on five key areas for R&D by 2025, with over 160 projects in the pipeline, including 9 innovative drugs in Class 1, 2 in Phase I clinical trials, and 4 in Phase II clinical trials[61]. - The company emphasizes continuous innovation in product development, focusing on both innovative and generic drugs, as well as health food development[111]. - The company has established nearly 90 research platforms at national, provincial, and municipal levels, focusing on core technologies in traditional Chinese medicine and related fields[70]. - The company is actively pursuing new product development and clinical research, including a new oral drug for cancer-related fatigue[122]. Risk Management and Compliance - There are no significant risks that materially affect the company's operations during the reporting period, as detailed in the risk management section[5]. - The company has implemented a comprehensive risk management system to identify, assess, and manage significant risks, ensuring regular monitoring and reporting to the board[161]. - The internal control evaluation report for the fiscal year 2025 was approved by the audit committee on March 20, 2026, confirming the adequacy and effectiveness of the internal control and risk management systems[160]. - The company has established a complete insider information handling procedure and internal control measures to prevent insider trading and ensure compliance with disclosure obligations[166]. Governance and Leadership - The company operates independently from its controlling shareholder, Guangzhou Pharmaceutical Group, with a complete business structure and independent operations[167]. - The current board members have extensive experience in management, compliance, and strategic planning, contributing to the company's governance[175][176]. - The company has a governance structure that guarantees equal rights for all shareholders, especially minority shareholders[170]. - The management team includes Tang Heping, who has a strong background in auditing and financial management, and will contribute to the company's strategic planning[180]. - The company has appointed several experienced executives, including Cheng Ning as Vice Chairman and Director, with extensive backgrounds in financial management and corporate governance[178]. Product Portfolio and Market Position - The company has a diversified business structure covering modern Chinese medicine, chemical pharmaceuticals, natural beverages, and medical services, with a focus on the pharmaceutical health industry[29]. - The company owns 13 traditional Chinese medicine brands, with 11 being over a century old, indicating strong brand recognition and market presence[30]. - The company’s antibiotic product line, branded as "抗之霸," is positioned as the leading oral antibacterial drug in China, showcasing its market leadership in this segment[31]. - The company’s natural beverage brand, Wanglaoji, has maintained the top position in the herbal tea industry for nine consecutive years, reflecting its strong brand value and market share[33]. Financial Health and Investments - The total assets at the end of 2025 amounted to RMB 84.51 billion, up 3.46% from RMB 81.68 billion in 2024[17]. - The company's total liabilities increased to RMB 44.43 billion, a 1.17% rise from RMB 43.91 billion in 2024[17]. - The net cash flow from operating activities for 2025 was negative at RMB (232.46 million), a significant decline of 106.75% from RMB 3.44 billion in 2024[17]. - The company has established a comprehensive pharmaceutical distribution network, serving over tens of thousands of clients across more than 30 provinces in China[69]. Shareholder Engagement and Compensation - The company ensures equal treatment of all shareholders and protects their rights, adhering to relevant laws and regulations for shareholder meetings[170]. - The total actual remuneration for all directors and senior management at the end of the reporting period amounted to RMB 6.6855 million[198]. - The company emphasizes the importance of performance-based compensation for its executives, which includes various components such as bonuses and insurance[192]. - The decision-making process for director and senior management remuneration involves the board and the remuneration committee, which considers industry standards and individual performance[198].

Financial Performance - The company's operating revenue for 2025 was CNY 5,229,190,487.41, a decrease of 2.05% compared to CNY 5,338,741,595.35 in 2024[28] - The total profit for the year was CNY 1,171,039,425.48, reflecting a growth of 6.18% from CNY 1,102,848,249.28 in the previous year[28] - The net profit attributable to shareholders was CNY 1,166,182,575.00, an increase of 7.26% compared to CNY 1,087,210,049.06 in 2024[28] - The company's total assets at the end of 2025 were CNY 8,958,219,053.33, a slight decrease of 0.19% from CNY 8,975,122,997.23 in 2024[28] - The net assets attributable to shareholders increased to CNY 8,003,251,978.48, up by 2.64% from CNY 7,797,275,364.17 in 2024[28] - Basic earnings per share for 2025 were CNY 0.656, representing a 7.19% increase from CNY 0.612 in 2024[29] - The weighted average return on net assets was 14.90%, an increase of 0.57 percentage points from 14.33% in 2024[29] - The cash flow from operating activities was CNY 1,240,486,450.40, down 16.96% from CNY 1,493,811,338.89 in 2024[28] - The company reported a decrease of 4.48% in net profit after deducting non-recurring gains and losses, totaling CNY 1,039,248,067.30 compared to CNY 1,087,961,496.13 in 2024[28] Dividend Distribution - The cash dividend proposed is CNY 5.5 per 10 shares, resulting in a total cash dividend distribution of CNY 977,723,949.95, with a cash dividend payout ratio of 83.84%[7] - The company provided cash dividends of 0.55 yuan per share, totaling 978 million yuan, with a dividend payout ratio of 89.93%[54] - The company has a cash dividend policy that complies with relevant regulations, with a clear dividend standard and a distribution ratio of 83.84% of the net profit[155] Agricultural Operations - The company engaged in various agricultural activities, including the cultivation and sale of grains, beans, and oilseeds, as well as agricultural technology services[42] - The company’s grain and bean total production reached 12.17 billion jin in 2025, achieving a stable increase in production capacity[48] - Agricultural machinery total reached 343,400 units, with a total power of 3.883 million kilowatts, achieving a mechanization level of over 99%[48] - The company operates 16 agricultural subsidiaries, producing high-quality crops such as rice, corn, and soybeans, with a total production of 12.17 billion jin[60] - The company has established a comprehensive agricultural technology service system, including 16 agricultural technology promotion centers[61] Research and Development - Total research and development (R&D) investment amounted to CNY 100.62 million, representing 1.92% of total operating revenue, with capitalized R&D accounting for 5.89% of the total[92] - The company is focusing on technological innovation to enhance agricultural productivity and competitiveness, collaborating with research institutions to promote applicable technology[55] - The company is focusing on high-quality agricultural development and the cultivation of new productive forces, emphasizing research on high-yield cultivation techniques and smart agriculture technologies[94] Financial Management - The company’s investment income (after tax) was 132.7 million yuan, a decrease of 40.96 million yuan year-on-year[52] - The company has a fixed asset book value of 27.23 million yuan that lacks property ownership certificates, primarily due to historical reasons related to planning and fire safety procedures[103] - The company has entrusted a total of CNY 4,000 million in bank wealth management products, with a return of CNY 4,958,904.11[195] - The company holds bank wealth management products with a total unexpired balance of CNY 3,640 million, with no overdue amounts[196] Legal and Compliance - The company has not reported any significant legal violations or penalties during the reporting period[189] - There were no penalties imposed by securities regulatory authorities in the past three years[135] - The company has not reported any significant deficiencies in internal controls during the reporting period[160] - The company has established a rigorous governance structure and operational rules, ensuring effective division of responsibilities and checks and balances[118] Management and Governance - The company has a total of 11 independent directors, ensuring diverse oversight and governance[131] - The board of directors includes members with extensive experience in various sectors, enhancing strategic decision-making[131] - The company has appointed new executives, including two vice presidents, to strengthen its management team[134] - The company has implemented a performance assessment and compensation management system for its executives, aligning with its operational performance[151] Future Outlook - The company aims to achieve an operating income of 5.491 billion yuan and a total profit of 1.152 billion yuan in 2026, with a total grain and bean production target of 6.123 million tons[112] - The company plans to leverage national policies that support agricultural innovation and capital operations, which are expected to provide new opportunities for growth[104] - The company plans to reduce the provision for employee education expenses from 2.5% to 1.5% of total wages, expected to increase profit by approximately CNY 5.6 million in 2026[172] Legal Disputes - The company is currently involved in multiple ongoing litigation cases, with the total amount in dispute exceeding CNY 200 million, reflecting potential financial implications[177] - The company has successfully executed a partial recovery of CNY 800,000 from a previous litigation case, with further amounts still pending execution[177] - The company has faced challenges in executing judgments due to the lack of available assets from defendants in several cases, which may affect cash flow[177] - The company has highlighted discrepancies in the court's assessment of its asset values, arguing that the court's conclusions were erroneous[186]

Financial Performance - The company's operating revenue for 2025 reached ¥437,998,898.25, an increase of 44.68% compared to ¥302,729,514.81 in 2024[21]. - The total profit for 2025 was ¥124,984,134.10, representing a significant increase of 137.94% from ¥52,527,554.47 in 2024[21]. - Net profit attributable to shareholders for 2025 was ¥102,037,073.61, up 147.96% from ¥41,150,745.84 in 2024[21]. - The net profit after deducting non-recurring gains and losses was ¥100,322,432.25, a 161.64% increase from ¥38,343,442.86 in 2024[21]. - The company's total assets as of the end of 2025 were ¥2,083,316,926.92, a 4.54% increase from ¥1,992,903,335.46 in 2024[21]. - The net assets attributable to shareholders at the end of 2025 were ¥1,890,097,190.33, reflecting a 5.42% increase from ¥1,792,961,454.97 in 2024[21]. - Basic earnings per share for 2025 were ¥0.60, a 150.00% increase from ¥0.24 in 2024[22]. - The company's revenue reached 437.99 million yuan, a year-on-year increase of 44.68%[56]. - Net profit attributable to shareholders was 102.04 million yuan, up 147.96% year-on-year[56]. Dividend Policy - The company plans to distribute a cash dividend of 1.85 RMB per 10 shares, totaling approximately 31.39 million RMB, which represents 30.76% of the net profit attributable to shareholders[5]. - The cash dividend for 2025 represents 30.76% of the net profit attributable to shareholders in the consolidated financial statements, which is 102,037,073.61 CNY[164]. - The cumulative cash dividends over the last three accounting years amount to 44,090,746.65 CNY, with an average annual net profit of 24,692,664.48 CNY, resulting in a cash dividend ratio of 178.56%[165]. Research and Development - R&D expenses amounted to 33.41 million yuan, an increase of 33.61% year-on-year[58]. - The company has accumulated R&D expenditures of 80,887,721.70 CNY over the last three accounting years, which accounts for 9.24% of total revenue[165]. - The company has applied for 8 invention patents, 9 utility model patents, and 4 software copyrights during the reporting period, focusing on core technologies in silicon component precision processing and silicon carbide coating technology[69]. - The company has a cumulative total of 141 patent applications, with 119 granted, indicating a strong focus on innovation and technology development[71]. - The company is committed to deepening the integration of R&D results with production processes, which enhances product market competitiveness[70]. Market Position and Strategy - The company attributed the increase in operating revenue to the continued recovery of the semiconductor market, leading to increased orders[23]. - The company has established a leading position in the domestic silicon component market, entering the supply chains of major local storage chip manufacturers[35]. - The company is focused on developing silicon components for high-end processes required in 12-inch chips, leveraging its competitive advantages in technology and capacity[53]. - The company aims to capitalize on the anticipated growth in China's silicon component market, projected to reach RMB 7 billion by 2026[124]. - The company plans to enhance its silicon component business to leverage the increasing domestic demand for semiconductor manufacturing[125]. Operational Efficiency - The company has implemented a production model based on customer orders and self-stock, optimizing production and inventory management[36]. - The company has expanded production capacity in Quanzhou and Jinzhou to ensure timely delivery of bulk orders[35]. - The company has optimized its crystal growth process, improving production efficiency and increasing yield rates through targeted upgrades to key production equipment[65]. - The company has established a dual-factory layout in Quanzhou and Jinzhou, enabling efficient R&D collaboration and rapid response to customer customization needs[63]. Governance and Compliance - The company has established a robust governance structure, ensuring compliance with relevant laws and regulations while enhancing operational efficiency[133]. - The company emphasizes the importance of investor relations, ensuring all shareholders receive timely and accurate information to protect their rights[135]. - The company has maintained strict internal control systems, ensuring compliance with laws and regulations, and received a standard unqualified opinion in its internal control audit[176]. - The company has not faced any significant competition issues from controlling shareholders or related parties, ensuring operational independence[135]. Risks and Challenges - The company faces customer concentration risk, as its products are primarily sold to a limited number of domestic clients[82]. - The company is exposed to supplier concentration risk, relying on a few overseas suppliers for high-purity raw materials[82]. - The semiconductor industry is cyclical, and the company's performance is closely tied to market demand and geopolitical factors[87]. - The company is currently in the certification phase for its semiconductor products, which may impact financial stability due to high initial capital investment[86]. Sustainability and Social Responsibility - The company has initiated a new sustainability strategy aimed at reducing carbon emissions by 25% over the next five years[140]. - The company actively participated in community development and social responsibility initiatives, including education support and environmental awareness activities[178]. - The company is committed to deepening its ESG management system to promote sustainable development alongside business growth[179].

Financial Performance - In 2025, the company's net profit is expected to decline by 79.19% year-on-year, amounting to 6.28 million yuan, compared to a decrease of 23.89 million yuan from the previous year[3]. - The company's operating revenue for 2025 is projected to be 137.40 million yuan, representing a 16.67% decrease compared to the previous year[7]. - The company reported a total asset impairment loss of 606,600 yuan for the first three quarters of 2025[3]. - The company reported a total revenue of less than 200 million yuan, which poses a risk of delisting if losses occur in 2025, as per the Shanghai Stock Exchange's new delisting rules[25]. Production and Sales - The production volume of 27.5% hydrogen peroxide is estimated at 155,300 tons, reflecting an 8.21% year-on-year decline[7]. - In 2025, the company's hydrogen peroxide sales volume reached 145,890 tons, generating a total revenue of 11,819 million yuan, with an average selling price of 810.07 yuan per ton[10]. - The company's hydrogen peroxide production capacity is 160,000 tons, with projected production of 169,000 tons in 2024 and 155,000 tons in 2025, indicating stable operations despite a decline in sales prices affecting revenue in 2025[24]. Pricing and Profitability - The average selling price of 27.5% hydrogen peroxide decreased by 12.90% year-on-year, with a unit selling price of 810.07 yuan per ton[8]. - The gross profit margin for 27.5% hydrogen peroxide dropped to 5.99%, a decrease of 17.82 percentage points compared to the previous year[8]. - The gross profit margin for self-pickup in Guangxi was 11.99%, while for delivery it was 8.71%, indicating that self-pickup has a higher profitability compared to delivery methods[10][13]. - The gross profit margin for the overall sales was 5.99%, reflecting the impact of increased transportation costs and lower production volumes[10][20]. - The overall gross margin for the company is maintained at 5.99%, despite industry losses, due to better cost control compared to the industry average and higher selling prices in the South China region[24]. Costs and Expenses - The company reported a total manufacturing cost of 9,305.73 million yuan for 2025, with a unit cost of 616.03 yuan per ton[14]. - Direct material costs accounted for 77.42% of total costs, with hydrogen costs remaining stable at 244 yuan per cubic meter, while other chemical raw materials saw a slight decrease in prices[15][16]. - The energy costs increased by 8.62% due to higher annual maintenance efforts, leading to a rise in the comprehensive unit cost of electricity, water, and steam[15][21]. - Management expenses for the reporting period totaled 1,135.54 million yuan, showing a slight increase of 2.16% year-on-year, with significant changes in specific expense categories such as a 188.61% increase in repair costs[29]. - Research and development expenses decreased by 60.67% year-on-year to 50.50 million yuan, primarily due to the absence of technical service fees from previous projects[31]. Cash Flow and Liquidity - Interest income for the reporting period was 1,324.4 million yuan, with the majority coming from agreements with Liuzhou Bank, reflecting a strong correlation with the company's cash holdings of 4.32 billion yuan[30]. - The company has conducted liquidity stress tests on its cash reserves for 2024 and 2025, confirming the liquidity of its cash holdings[32]. - The asset-liability ratio is reported at 10%, with no interest-bearing debt, indicating a strong debt structure and a cash ratio of 7.44, reflecting ample liquidity and strong debt repayment capability[24]. Market and Strategic Outlook - The company faces risks from market price fluctuations and demand changes, as it operates primarily in the hydrogen peroxide sector, which has seen increased competition and a slowdown in downstream demand growth[24]. - The company plans to enhance market forecasting and supplier audits to further reduce procurement costs and improve profitability[16]. - The company plans to enhance profitability and operational stability through measures such as improving existing facilities, strengthening marketing management, and expanding into high-purity hydrogen peroxide markets[26]. Audit and Compliance - The annual audit for the company's 2025 financial statements is still ongoing, and discrepancies may exist between audited financial data and performance forecasts[35]. - The audit procedures include detailed checks on revenue recognition, cost expenses, and asset impairment assessments[36]. - The company emphasizes the importance of maintaining effective internal controls over revenue and expense recognition processes[35]. - The company is implementing targeted audit procedures to ensure compliance with auditing standards and to address significant risks identified in financial reporting[37].

Company Performance - Zijin Mining ranked 251st in the 2025 Forbes Global Public Companies and 4th among global metal mining companies, maintaining its position as the number one gold company[19]. - In the past year, Zijin Mining achieved a record net profit of 51.8 billion yuan, a year-on-year increase of 62%[20]. - The company reported a revenue of 34.91 billion yuan for 2025, reflecting a growth trajectory from previous years[29]. - Net profit for 2025 was CNY 63.82 billion, reflecting a 62.01% increase compared to CNY 39.39 billion in 2024[61]. - The net profit attributable to shareholders for 2025 was CNY 51.78 billion, up 61.55% from CNY 32.05 billion in 2024[61]. - The company's total assets increased by 29.10% to CNY 512.01 billion at the end of 2025, compared to CNY 396.61 billion at the end of 2024[61]. - The weighted average return on equity for 2025 was 33.04%, an increase of 7.15 percentage points from 25.89% in 2024[62]. - The net cash flow from operating activities for 2025 was CNY 75.43 billion, a 54.38% increase from CNY 48.86 billion in 2024[61]. - The company achieved a global social contribution value of 109.11 billion yuan, a year-on-year increase of 46%[156]. Strategic Goals and Future Plans - Zijin Mining aims to become a leading global mining company with a focus on green and high-tech operations[2]. - The company has outlined its strategic goals for 2026, focusing on industry trends and potential risks[19]. - Zijin Mining aims to rank among the top three globally in copper and gold production by 2028, with a vision for substantial growth by 2035[22]. - The company plans to produce 109,000 tons of copper and 90 tons of gold by 2025, with significant increases in production expected in subsequent years[41]. - The company plans to accelerate the construction of key projects, including the Serbia Chukalu-Peggy copper-gold mine and the second phase of the Peru Arequipa copper mine, aiming for significant production increases[22]. - The company is exploring potential mergers and acquisitions to expand its market presence and resource base[84]. Technological Advancements - The company has achieved significant technological advancements, with 29 national invention patents and 26 provincial and ministerial-level scientific progress awards[19]. - The company is focusing on technological innovation, including AI applications in mining operations, to drive efficiency and productivity[23]. - The company has made significant advancements in technology, including the industrial application of lithium extraction technology and improvements in mining efficiency through AI and digital systems[154]. Sustainability and ESG Commitment - The company emphasizes its dedication to sustainable development, as detailed in the 2025 Sustainability Report[13]. - Zijin Mining is committed to enhancing its ESG performance and integrating ESG governance into its strategy and operations[25]. - The company is focused on sustainable mining practices as outlined in its sustainability report[82]. - The company is committed to building a complete mining value chain that emphasizes green, intensive, low-carbon, and circular development[182]. Resource Management and Production - The company holds over 4,600 tons of gold, approximately 110 million tons of copper, and over 12 million tons of zinc (lead), ensuring a strong resource base for sustainable development[21]. - The total resource reserves include 1,996 tons of gold, 5,661,000 tons of copper, and 797,000 tons of lithium, indicating a strong resource base for future growth[45]. - The company has completed the acquisition of key gold mines, which are expected to increase annual gold production by approximately 37 tons upon reaching full capacity[43]. - The company has established a global qualified personnel team for geological exploration, with 58 qualified individuals under the CRIRSCO framework by 2025[68]. - The company has developed advanced geological exploration technologies, including a three-dimensional electromagnetic system and drone magnetic surveying, recognized by the Ministry of Natural Resources[72]. Financial Overview - The financial report indicates a commitment to transparency and accuracy, with a standard unqualified audit report issued by Deloitte[5]. - The total profit before tax is projected to reach 10.14 billion yuan by 2025, indicating a strong upward trend in profitability[31]. - The company plans to distribute a cash dividend of 3.8 CNY per 10 shares (tax included), pending approval at the 2025 annual shareholders' meeting[6]. - The company reported a significant increase in financial assets, with trading financial assets rising to CNY 9.98 billion by the end of 2025, up from CNY 5.99 billion at the beginning of the year[65]. Market Trends and Economic Factors - The average price of gold in 2025 is projected to reach $3,439 per ounce, a year-on-year increase of 44%[162]. - The average price of copper in 2025 is projected to be $9,945 per ton, with a year-on-year increase of 8.7%[162]. - During the reporting period, copper prices surged over 40% year-to-date, reaching a historical high by year-end, with a low of $8,539 per ton in April 2025 due to U.S. tariff announcements[166][168]. - Zinc prices experienced a downward trend throughout the year, with a peak of $3,220 per ton near year-end, but faced significant downward pressure overall[170]. Community and Social Responsibility - The company has achieved a community investment of 1.09 billion CNY in 2025, reflecting its commitment to social responsibility[47]. - The company has established a global operational management system, with a local employment rate of 96% and a significant increase in the localization of the management team[155].

Financial Performance - The company's operating revenue for 2025 reached ¥2,857,714,112.47, representing a 14.94% increase compared to ¥2,486,211,022.64 in 2024[16] - Net profit attributable to shareholders for 2025 was ¥531,919,355.42, up 16.43% from ¥456,854,970.90 in 2024[16] - The net cash flow from operating activities significantly increased by 153.15%, totaling ¥686,654,970.95 compared to ¥271,240,913.44 in 2024[16] - Basic earnings per share for 2025 were ¥2.08, an increase of 8.90% from ¥1.91 in 2024[16] - Total assets at the end of 2025 amounted to ¥4,443,639,197.41, reflecting a 12.25% growth from ¥3,958,683,616.29 at the end of 2024[16] - The company's net assets attributable to shareholders decreased by 1.39% to ¥3,115,386,707.83 from ¥3,159,314,538.24 in 2024[16] - The weighted average return on net assets for 2025 was 17.02%, slightly down from 18.03% in 2024[16] Revenue Breakdown - Manufacturing sector contributed ¥2,821,252,889.58, accounting for 98.72% of total revenue, with a year-on-year growth of 15.20%[52] - Precision flexible components generated ¥2,395,163,177.95, making up 83.81% of total revenue, with a growth rate of 16.30%[52] - Domestic revenue increased by 21.63% to ¥1,003,725,071.94, while overseas revenue grew by 11.62% to ¥1,853,989,040.53[52] Cash Flow and Investments - Operating cash inflow reached ¥3,052,476,412.81 in 2025, a 27.74% increase from ¥2,389,606,315.78 in 2024, while net cash flow from operating activities surged by 153.15% to ¥686,654,970.95[67] - Investment cash inflow rose significantly to ¥5,029,346,156.74 in 2025, up 158.66% from ¥1,944,374,611.43 in 2024, with net cash flow from investment activities turning positive at ¥308,117,258.62[67] - Financing cash inflow decreased by 48.12% to ¥424,813,100.14 in 2025, while financing cash outflow surged by 176.95% to ¥666,076,015.53, resulting in a net cash flow from financing activities of -¥241,262,915.39[68] R&D and Innovation - The company has a strong focus on R&D, having obtained multiple patents and forming a proprietary intellectual property system to maintain technological leadership[43] - R&D investment amounted to ¥130,762,213.04 in 2025, reflecting a 16.12% increase from ¥112,611,365.05 in 2024, with R&D investment accounting for 4.58% of operating revenue[66] - The company completed the development of a no-bubble optical adhesive technology, achieving a bubble defect rate of ≤0.1% and positioning accuracy of ≤±0.05mm[59] - The company is focusing on enhancing market competitiveness through various new technologies and products, including a pneumatic locking mold mechanism that improves mold change efficiency by 20%[59] Market and Sector Focus - The company focuses on three main sectors: smart terminals, data communication and computing equipment, and new energy, while maintaining technological innovation[104] - The new energy sector is expected to see a cumulative installed capacity of 373 GWh by the end of 2025, representing a growth of 111.4% compared to 2024[31] - The global smartphone shipment is projected to reach 1.26 billion units in 2025, reflecting a year-on-year growth of 1.9%[26] Shareholder Returns - The company plans to distribute a cash dividend of ¥5 per 10 shares, based on a total of 243,759,242 shares[4] - For the fiscal year 2025, the company intends to distribute a cash dividend of ¥5 per 10 shares, amounting to ¥121,879,621.00, which represents 22.91% of the net profit attributable to ordinary shareholders[112] - The company has implemented a three-year shareholder return plan (2023-2025) to ensure a balance between strategic development and shareholder returns[111] Governance and Management - The board of directors consists of 12 members, including 4 independent directors, and held 13 board meetings during the reporting period[120] - The company has established a robust investor relations management system, ensuring effective communication with investors through multiple channels[126] - The management team is stable and forward-looking, focusing on talent development through a combination of internal training and external recruitment[49] Employee and Compensation Policies - The total number of employees at the end of the reporting period is 2,365, with 855 in the parent company and 1,510 in major subsidiaries[163] - The salary policy is based on fairness, reasonableness, and incentives, with a structured approach to salary management involving the board of directors and human resources[165] - Total compensation for all directors and senior management during the reporting period amounted to CNY 15.07 million[155] Compliance and Risk Management - The company has implemented a comprehensive internal control system to ensure compliance with laws and regulations, optimizing governance and risk management[198] - The internal control system is designed to ensure that all departments adhere to regulations and complete operational tasks effectively[199] - No significant internal control deficiencies were reported during the reporting period[200]

Financial Performance - The company's operating revenue for 2025 was ¥460,424,830.18, a decrease of 2.76% compared to ¥473,483,218.90 in 2024[22] - Net profit attributable to shareholders for 2025 increased by 31.94% to ¥64,985,897.94 from ¥49,253,369.52 in 2024[22] - The net profit after deducting non-recurring gains and losses was ¥62,905,363.26, reflecting a 33.40% increase from ¥47,156,286.73 in 2024[22] - The net cash flow from operating activities rose by 33.67% to ¥84,894,046.03 compared to ¥63,511,120.48 in 2024[22] - Basic earnings per share increased by 37.50% to ¥0.22 from ¥0.16 in 2024[22] - Total assets at the end of 2025 were ¥1,107,891,830.42, a 1.97% increase from ¥1,086,534,605.98 at the end of 2024[22] - Net assets attributable to shareholders increased by 4.76% to ¥960,106,606.54 from ¥916,439,508.41 in 2024[22] Revenue and Sales - The company achieved operating revenue of 460.42 million, a decrease of 2.76% compared to the previous year[32] - Net profit attributable to shareholders increased by 31.94% to 64.99 million, while the net profit excluding non-recurring gains and losses rose by 33.40% to 62.91 million[32] - The revenue share of enteric-coated gelatin capsules significantly increased from 15.52% to 18.67%, driving overall business growth[33] - Domestic sales accounted for 85.08% of total revenue, while international sales decreased by 13.79% to CNY 68.67 million[51] - The company's revenue from the pharmaceutical hollow capsules segment was ¥460,424,830, a decrease of 2.76% year-over-year, with a gross margin of 29.75%, which increased by 4.23% compared to the previous year[53] Cost Management and Efficiency - The company optimized procurement strategies, implementing a centralized purchasing model that led to a steady decline in procurement costs[32] - Inventory balance decreased by 24.39% to 75.76 million, improving inventory turnover and operational efficiency[33] - The company focused on cost control and efficiency improvement to counteract the pressure from declining product prices[32] - The cost of raw materials accounted for 58.38% of total operating costs, decreasing by 15.26% year-over-year, while labor costs increased by 11.66% to ¥37,406,556.26[56] Market and Competitive Landscape - The competitive landscape in the hollow capsule industry remains intense, with ongoing price reductions impacting overall profitability[30] - The overall external market environment remains complex and challenging, with increased competition due to anti-dumping measures in the U.S.[30] - The company is committed to enhancing its high-end product offerings and market promotion efforts to drive revenue growth[33] - The company aims to expand its market share and enhance core competitiveness by focusing on high-quality development and continuous innovation[35] Research and Development - The company invested CNY 12.65 million in R&D, resulting in 5 patent applications and 4 patents granted, enhancing its innovation capabilities[46] - The company is in the pilot stage of developing enteric HPMCP hollow capsules, aiming for commercial production to increase product variety[62] - The company plans to strengthen collaborations with universities and research institutions to drive innovation in functional pharmaceutical capsules[77] Governance and Management - The company held 2 shareholder meetings and 6 board meetings during the reporting period, expanding the board from 7 to 9 members, including 3 independent directors[86] - The company has experienced changes in senior management, including the resignation of General Manager Yu Chaobiao due to term completion on December 18, 2025[95] - The company’s governance practices were in compliance with relevant laws and regulations, ensuring the protection of minority shareholders' rights[108] - The company has established independent operational management structures, ensuring no overlap with controlling shareholders or related enterprises[91] Internal Controls and Compliance - The company has established a comprehensive internal control system, with no significant defects reported during the period[121] - The company has maintained compliance with the internal control standards set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange[121] - The company has implemented key internal controls related to revenue recognition to mitigate the risk of inappropriate revenue recognition practices[183] Shareholder Relations and Dividends - The company plans to distribute a cash dividend of ¥0.53 per 10 shares, totaling approximately ¥15,855,000 based on 299,098,170 shares[5] - The total distributable profit for the company was 500,095,668.14 CNY, with the cash dividend amounting to 100% of the total profit distribution[119] - The company has ensured that minority shareholders have had sufficient opportunities to express their opinions and that their legal rights have been adequately protected[119] Future Outlook - The focus for 2026 includes expanding into high-end products like enteric-coated capsules and plant-based capsules, with a strategic emphasis on international market development[76] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million yuan for potential deals[104] - The company has provided a positive outlook for the next quarter, projecting a revenue increase of 10% to 1.32 billion yuan[104]

Financial Performance - The company's operating revenue for 2025 was CNY 3,369,908,369.13, a decrease of 3.85% compared to CNY 3,504,986,068.51 in 2024[20]. - The total profit for 2025 was CNY 391,057,169.72, reflecting a slight decrease of 0.40% from CNY 392,621,466.78 in the previous year[20]. - The net profit attributable to shareholders for 2025 was CNY 359,841,141.67, down 0.65% from CNY 362,178,656.98 in 2024[20]. - The basic earnings per share for 2025 were CNY 2.37, a decrease of 0.42% from CNY 2.38 in 2024[21]. - The weighted average return on net assets for 2025 was 14.26%, down 1.42 percentage points from 15.68% in 2024[21]. Revenue Breakdown - The pharmaceutical commercial sector's revenue decreased by 23.37%, while the pharmaceutical industrial sector's revenue grew by 15.92%[21]. - In Q1 2025, the company's operating revenue was approximately CNY 892.08 million, with a net profit attributable to shareholders of CNY 110.18 million[24]. - In Q2 2025, the operating revenue increased to approximately CNY 912.51 million, maintaining a net profit of CNY 110.45 million[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses in Q3 2025 was CNY 60.22 million, a decrease compared to previous quarters[24]. - The company achieved a revenue of 3.505 billion yuan in the Chinese herbal medicine industry, ranking 24th among listed companies in the sector for the 2024 fiscal year[38]. Cash Flow and Assets - The net cash flow from operating activities increased by 17.19% to CNY 274,529,817.46, primarily due to increased sales collections in the pharmaceutical industrial sector[20][21]. - The company's total assets at the end of 2025 were CNY 4,526,894,996.61, a 5.83% increase from CNY 4,277,629,406.13 in 2024[20]. - The net assets attributable to shareholders increased by 9.08% to CNY 2,656,393,006.53 compared to CNY 2,435,305,586.88 in 2024[20]. Research and Development - The company has made significant investments in R&D, focusing on innovative traditional Chinese medicine, with five new drug clinical trials currently underway[38]. - The company filed for 7 new patents and received 5 authorized patents during the reporting period, indicating a strong focus on R&D[75]. - The total R&D investment amounted to 115,656,436.32, representing 3.43% of total revenue[95]. - The company is focusing on innovative R&D in traditional Chinese medicine, particularly in pediatrics, gynecology, and chronic diseases[121]. Product Development and Launches - The company is focusing on expanding its pediatric product line under the "Longmu" brand, with a key product being Longmu Bone Strengthening Granules, which is a unique offering in the market[32]. - The company has launched several new prescription products, including Baidu Shengji San and Qirui Weishu Capsules, which are expected to strengthen the product foundation for future growth[34]. - The company has developed a new product, Longmu Zhuanggu Granules, aimed at treating pediatric rickets and related conditions, with a patent valid until July 22, 2034[116]. Market Strategy - The company plans to optimize its business structure, focusing on high-margin products and new product sales[21]. - The OTC product line, particularly the "Jianmin" brand, is expected to see continued growth, with products like 便通胶囊 and 健脾生血颗粒 gaining market traction[33]. - The company aims to enhance its market presence in the pediatric segment, targeting over 40 existing pediatric products in 2025[33]. Compliance and Governance - The company emphasizes compliance with securities market laws and regulations to prevent future violations[173]. - The company has established strict insider information management systems, with no insider trading incidents reported during the period[165]. - The company has implemented a cash dividend policy, distributing a total of RMB 138,058,740 to shareholders, which corresponds to a cash dividend of RMB 9 per 10 shares[187]. Challenges and Risks - The pharmaceutical industry faces challenges such as intensified price competition and increased compliance costs, which may pressure profit margins[146]. - The company faces risks from industry policy changes, intensified market competition, and raw material price fluctuations, necessitating proactive risk management strategies[154][155]. - New product introductions may not meet expectations due to market demand and consumer recognition challenges, requiring thorough market research and tailored sales strategies[155].